Resources

CAR T-Cell Therapy Perceptions

Subsequent to a report of a chromosomal abnormality in CAR T-cells in a patient treated in an allogeneic CAR T-cell therapy clinical trial, the FDA has placed a hold on allogeneic CAR T-cell therapy clinical trials being conducted by that company.

InCrowd wanted to understand how this FDA action affected oncologists’ and hematologists’ perceptions of CAR T-cell therapy in both the allogeneic and autologous spaces and gene therapy in general.

Download the latest InCrowd Instant Insights report to learn how 76 US oncologists, hematologists, and hematology-oncologists felt about the future of CAR T-Cell therapy and the impact of FDA actions on their perceptions of gene therapy. 

Please fill out the form below to access this content

Name(Required)
Consent
This field is for validation purposes and should be left unchanged.

Related Resources

The Impact of Technology on Mental Healthcare

The Impact of Technology on Mental Healthcare

Exploring Psychiatrist Opinions and Expectations Around the Rise in Digital Therapeutics to Treat Mental Health The National Institutes of Health (NIH) believe “technology has opened a new frontier in mental health support,” but questions remain around how...

read more
ESMO 2022 Real-Time Roundup

ESMO 2022 Real-Time Roundup

The 2022 Annual Meeting of the European Society for Medical Oncology (ESMO) took place in person from September 9th to the 13th. InCrowd wanted to learn from those Medical Oncologists and Hematology-Oncologists who attended the following two objectives: Explore which...

read more
ASCO 2022 Real-Time Roundup

ASCO 2022 Real-Time Roundup

The 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO) took place in person from June 3rd to the 7th. InCrowd wanted to learn from those oncologists who attended the following two objectives: Explore which tumor type/track had the most exciting...

read more